CTTQ

CTTQ Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating R&D, production, and sales. It is a well-known domestic R&D and production base for liver health drugs, a national key high-tech enterprise, and a key backbone enterprise of the Lianyungang New Medicine Industry Base under the National Torch Plan. In 2016, it ranked 16th on the China Pharmaceutical Industry Top 100 Enterprises list (selected and released by China Pharmaceutical Industry Information Center).

CTTQ has always regarded technological innovation as an important corporate development strategy and is one of the domestic pharmaceutical companies with significant investment in innovative drug research. CTTQ uses its research institute as a platform for innovation, and has successively established high-level R&D platforms such as the "Jiangsu Provincial Engineering Technology Research Center for New Liver Disease Drugs", the "Postdoctoral Research Station", and the "National Recognized Enterprise Technology Center", continuously enhancing its independent innovation capabilities. With the development of the enterprise and the improvement of R&D capabilities, CTTQ's annual R&D investment has exceeded 1 billion yuan. Currently, the research institute has more than 180 projects in progress, including over 30 Class 1 new drugs and over 20 biological drugs.

CTTQ has three production bases in Lianyungang, covering a total area of more than 800 mu, including an incubation base covering 160 mu, an API base covering more than 200 mu, and a preparation base covering 480 mu. CTTQ's preparation base obtained the first new version of GMP certificate in the country, and its solid dosage form workshop passed EU certification, receiving the EU-recognized GMP certification certificate issued by the German Medicines Authority. The acquisition of these certificates marks that the quality and management level of the enterprise's drug production are at the forefront of the national pharmaceutical industry. Currently, CTTQ is preparing for the international market entry of its four flagship products, and these drugs will become new tools for CTTQ to enter the international market in the future.

CTTQ's products cover treatment areas such as liver diseases, tumors, respiratory infections, digestive diseases, and more. Sixteen products with annual sales exceeding 100 million yuan form a "billion-yuan product group", among which two products have annual sales exceeding 2 billion yuan: the national Class 1 new drug Magnesium Isoglycyrrhizinate Injection (Tianqing Gанmei) and the first domestically listed Entecavir Dispersible Tablets (Runzhong). In addition to its strong liver disease field, CTTQ has also formed a unique product line in the anti-tumor field. The hematological tumor drugs Decitabine, Imatinib, and Dasatinib are the first domestic generics; the solid tumor drug Capecitabine has been approved for marketing, and the highly anticipated innovative drug Anlotinib, an original research drug in the Chinese oncology field, has been officially launched and is expected to become the standard third-line treatment for patients with advanced non-small cell lung cancer. The fields of respiratory, antibiotics, and endocrine will also be key directions for the enterprise's future development.

In future development, CTTQ Pharmaceutical will continue to strengthen the building of core competitiveness, establish and improve a scientific and efficient R&D system, so that the company's R&D level always keeps pace with international frontiers. It will develop the enterprise into a large pharmaceutical group with R&D strength ranking in the top five and comprehensive strength in the top ten among national pharmaceutical enterprises; and initiate an internationalization strategy to build the enterprise into a technology-based, pharmaceutical-centric international company.